肺心病急性加重期采用低分子肝素联合酚妥拉明治疗的临床疗效分析.docVIP

精品论文 参考文献 肺心病急性加重期采用低分子肝素联合酚妥拉明治疗的临床疗效分析 阿依提拉汗?艾力 (新疆乌鲁木齐市水磨沟区人民医院 830017) 【摘要】目的：评价肺心病急性加重期采用低分子肝素联合酚妥拉明治疗的的临床效果。方法:选取入住我院进行治疗的肺心病急性加重期患者200名，按照完全随机抽样的方法，随机分为2个组：对照组、实验组。对照组采用常规疗法，实验组在常规疗法基础上采用低分子肝素和酚妥拉明的联合疗法。观察并比较两组患者的治疗情况。结果：患者经过治疗后，实验组总有效率为88.00%，对照组总有效率为49.00%，实验组明显高于对照组，具有统计学意义(Plt;0.05)；实验组血液全血粘度、血浆粘度和红细胞聚集指数在治疗前后具有显著差异(Plt;0.05)且较对照组三项指标均具有显著性差异，具有统计学意义(Plt;0.05)。结论：在对肺心病急性加重期患者进行治疗的过程中，通过采用低分子肝素和酚妥拉明的联合治疗，效果显著，急性加重期患者疾病状况明显改善，可在临床上广泛应用。 【关键词】肺心病 急性加重期 低分子肝素 酚妥拉明 【中图分类号】R541.5 【文献标识码】A 【文章编号】2095-1752（2014）19-0068-02 Analyzed the clinical effect of low molecular heparin combine with phentolamine in treatment of acute exacerbation of pulmonary heart disease 【Abstract】Objective: To evaluated the low molecular heparin combine with phentolamine in treatment of acute exacerbation of pulmonary heart disease. Methods: 200 patients with acute exacerbation of pulmonary heart disease in our hospital were selected, and divided them into control group and experimental group by randomly. The control group was treated by routine treatment, and the experimental group was treated by low molecular heparin combine with phentolamine on the basis of routine treatment. To observed and compared the treatment of two groupsrsquo; patients. Results: The patients after treatment, the total efficiency of experimental group was 88%, the total efficiency of control group was 49%, the experimental group was significantly higher than control group, differences were statistically significant(Plt;0.05); the blood viscosity of whole blood, plasma viscosity and erythrocyte aggregation index of experimental group before and after therapy had significant differences(Plt;0.05),and compared with the control group of three indicators, differences were statistically significant(Plt;0.05).Conclusion: In the course of acute exacerbation of pulmonary heart disease patients treated by combination therapy using low